JNM
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Larikka, M. J.
Right arrow Articles by Balter, H. S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Larikka, M. J.
Right arrow Articles by Balter, H. S.
Journal of Nuclear Medicine Vol. 44 No. 8 1368-1369
© 2003 by Society of Nuclear Medicine


Letters to the Editor

Specificity of 99mTc-Ciprofloxacin Imaging

Martti J. Larikka, MD1, Aapo K. Ahonen, MD, PhD2, Onni Niemelä, MD, PhD3, Juhani A. Junila, MD, PhD4, Martti M. Hämäläinen, MD, PhD4 and Hannu P. Syrjälä, MD, PhD4

1 Oulu University Hospital Oulu, Finland LP Central Hospital Kemi, Finland
2 Oulu University Hospital Oulu, Finland Helsinki University Central Hospital Helsinki, Finland
3 Oulu University Hospital Oulu, Finland EP Central Hospital Seinäjoki, Finland
4 Oulu University Hospital Oulu, Finland

TO THE EDITOR:

We have read with interest the letters by Das et al. (1) and Pauwels et al. (2) regarding the characteristics of 99mTc-ciprofloxacin imaging for detection of infections. The above correspondence cites our previous work, and the latter group was "surprised to hear that only 40% specificity was obtained using scintigraphic data after 4 h, because this information has never been included in reports by the London group and puts a different complexion on the reliability of previously published clinical data."

We would like to correct the inaccuracy in referring to our original data (3). Our work shows that in patients with hip prosthesis infections, the specificity of 99mTc-ciprofloxacin imaging was 41% at 1-h imaging, 68% at 4-h imaging, and 95% at 24-h imaging—for a sensitivity of 100%. Our data are thus in good agreement with previously published clinical data, and the citation of a 41% specificity after 4 h may have inspired Pauwels et al. to a more subjective interpretation than one allowed by the results of our original study.

REFERENCES

  1. Das SS, Wareham DW, Britton KE. 99mTc-Labeled antimicrobial peptides for detection of bacterial and Candida albicans infections [letter] [published correction appears in J Nucl Med. 2002;43:1376.]. J Nucl Med. 2002;43:1125.[Free Full Text]
  2. Pauwels EKJ, Welling MM, Nibbering PH, Lupetti A, Balter HS. 99mTc-Labeled antimicrobial peptides for detection of bacterial and Candida albicans infections [reply]. J Nucl Med. 2002;43:1126–1127.
  3. Larikka MJ, Ahonen AK, Niemelä O, et al. Comparison of 99mTc ciprofloxacin, 99mTc white blood cell and three-phase bone imaging in the diagnosis of hip prosthesis infections: improved diagnostic accuracy with extended imaging time. Nucl Med Commun. 2002;23:655–661.[Medline]

 
Ernest K.J. Pauwels, DSc1, Mick M. Welling, PhD1, Peter H. Nibbering, PhD1, Antonella Lupetti, MD2 and Henia S. Balter, PhD3

1 Leiden University Medical Centre Leiden, The Netherlands
2 Università degli Studi di Pisa Pisa, Italy
3 Centro de Investigaciones Nucleares Montevideo, Uruguay

REPLY:

We read with interest the letter by Larikka et al. referring to our reply to a letter to the editor (1,2). In this reply, we expressed our surprise when Das et al., referring to data by Larikka et al. (3), mentioned "an increase in specificity from 41% to 95% when a 24-h image was combined with a 4-h image... . " From the present letter by Larikka et al., we understand that the real specificity at 4 h amounts to 68% instead of 41% as reported by Das et al., who cited the work in the wrong way and put us on the wrong track. Therefore, we appreciated that Das et al., in an erratum published 2 mo after the publication of our reply, corrected their inaccuracy (1). Nevertheless, also in the abstract by Larikka et al., this information was not clearly stated since it is written "In 13 (59%) of the non-infected patients, non-specific uptake of 99mTc ciprofloxacin was found in the 1-h and 4-h images, which disappeared, however, in the 24-h images." The data of Larikka et al. are in full agreement with our preclinical observations at early intervals of injection of radiolabeled ciprofloxacin. Indeed, their and our studies pointed out that 99mTc-ciprofloxacin cannot discriminate between infectious and sterile inflammatory processes at 1 h after injection of the tracer. Although Larikka et al. demonstrated an improved accuracy of 99mTc-ciprofloxacin with extended imaging time, in our experiments there was no need to improve any diagnostic accuracy with late images since 99mTc-labeled antimicrobial peptides were already able to distinguish infections from sterile inflammations 1 h after injection of the tracer (4). It should be realized that in our experiments, ciprofloxacin was used as a control, as stated before (4). Lastly, could Dr. Larikka and colleagues (including Britton as coauthor (3)) demonstrate where we made a "subjective interpretation"? In their letter, they did not provide evidence for this.

REFERENCES

  1. Das SS, Wareham DW, Britton KE. 99mTc-Labeled antimicrobial peptides for detection of bacterial and Candida albicans infections [letter] [published correction appears in J Nucl Med. 2002;43:1376.]. J Nucl Med. 2002;43:1125.
  2. Pauwels EKJ, Welling MM, Nibbering PH, Lupetti A, Balter HS. 99mTc-Labeled antimicrobial peptides for detection of bacterial and Candida albicans infections [reply]. J Nucl Med. 2002;43:1126–1127.
  3. Larikka MJ, Ahonen AK, Niemelä O, et al. Comparison of 99mTc ciprofloxacin, 99mTc white blood cell and three-phase bone imaging in the diagnosis of hip prosthesis infections: improved diagnostic accuracy with extended imaging time. Nucl Med Commun. 2002;23:655–661.
  4. Welling MM, Lupetti A, Balter HS, et al. 99mTc-Labeled antimicrobial peptides for detection of bacterial and Candida albicans infections. J Nucl Med. 2001;42:788–794.[Abstract/Free Full Text]



This article has been cited by other articles:


Home page
JNMHome page
D. Rubello, A. M. Peters, and J. R. Ballinger
Timing for Evaluating "Specific" Binding of 99mTc-Sulesomab in Peripheral Bone Infection
J. Nucl. Med., February 1, 2005; 46(2): 382 - 383.
[Full Text] [PDF]


This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Larikka, M. J.
Right arrow Articles by Balter, H. S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Larikka, M. J.
Right arrow Articles by Balter, H. S.


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
JOURNAL OF NUCLEAR MEDICINE TECHNOLOGY THE JOURNAL OF NUCLEAR MEDICINE